2cureX plans to get listed at Nasdaq Stockholm First North stock exchange in November 2017.
2cureX AB (“2cureX”) announces today that the company plan a public issue of shares ahead of applying to get listed at the Nasdaq Stockholm First North. 2cureX is in the process of launching a clinical validation trial on colorectal cancer patients in Denmark, Germany and the UK. A successful outcome of this trial will pave the way for market launch of the IndiTreat™ product.2cureX is a MedTech company that has developed IndiTreat™, a technology that can match the individual cancer patient with an efficacious treatment. IndiTreat™ has been developed and tested in more than 900 patients with